Alkermes plc. (ALKS) stock

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value

$46.98−0.91 (-1.90%)

Close on Nov 12, 2026Market cap $7.88BP/E 123.6Yield –

Alkermes pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Alkermes's pe ratio was 126.0× on Nov 11, 2026, against 14.6× a year earlier. Over the last 5 years it ranged from 9.2× to 441.0×, with a median of 42.4×.

PE Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	126.0×	+112.2
2025	Dec 31, 2025	13.9×	−0.7
2024	Dec 31, 2024	14.6×	−7.8
2023	Dec 29, 2023	22.4×	−155.5
2016	Jan 29, 2016	177.8×	−263.2
2015	Dec 31, 2015	441.0×	+115.7
2014	Dec 31, 2014	325.3×	+99.4
2013	Dec 31, 2013	225.9×	–

Where these numbers come from

Parsed from the XBRL in Alkermes's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on May 15, 2000
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALKS.

Compare: ALKS vs ACAD · ALKS vs SUPN · ALKS vs AXSM · ALKS vs INSM · ALKS vs AMRX

Revenue growth10.8% · median 16.3%

Gross margin84.6% · median 85.0%

Operating margin7.0% · median 10.2%

Net margin4.0% · median 4.2%

Company	Revenue	Growth
AMRX	$3.20B	+8.9%
ALKS	$1.67B	+10.8%
INSM	$1.52B	+240.0%
SUPN	$1.37B	+16.3%
ACAD	$1.20B	+14.8%
AXSM	$865.27M	+54.2%

Company

Next earnings (est.): Feb 24, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2,050
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1520262

Advertisement
300 × 250

See a number that looks wrong?